Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
BMS defends Celgene buyout ahead of shareholder vote
ahead. Another high profile BMS investor, Brad Loncar’s Loncar Cancer Immunotherapy ETF, also made its opposition to the deal clear earlier this month.
Latest news
-
Roche gets FDA nod for Tecentriq in small cell lung cancer
Ending a 20-year drought in new therapies for patients. Roche continues to nibble away at the big lung cancer market with its cancer immunotherapy Tecentriq, picking up an FDA approval ... The US regulator has cleared Tecentriq (atezolizumab) in
-
Allergy Tx hit hard as birch pollen product stumbles
The UK biotech said this morning that the phase 3 B301 trial of its birch pollen allergy product failed to meet its primary objective, with no difference between the immunotherapy and ... Two phase 2 studies revealed a significant 32% reduction in
-
Keytruda adds another NSCLC approval in Europe
Squamous NSCLC completes first-line dominance
-
AZ to address Imfinzi setback, but sees potential with Tagrisso
Those who express a high TMB could carry more markers on the cancer cell surface that could make them vulnerable to cancer immunotherapy.
-
Celgene’s Abraxane fails pancreatic cancer trial
It secured another this week when the FDA cleared the drug in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) for triple-negative breast cancer – becoming the first immunotherapy regimen
More from news
Approximately 79 fully matching, plus 393 partially matching documents found.
Latest Intelligence
-
Brain power: fresh approaches to Alzheimer’s drug discovery
The development of immunotherapies has, in recent years, dominated our progress in tackling cancer and Alector’s approach in harnessing the power of the immune system to target neurodegeneration was a
-
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019? ... cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies.
-
Immunotherapy combination trials Q&A
By Chris Learn and Martin Lachs
-
AstraZeneca’s oncology renaissance
olaparib) plus biologic PD-L1 immunotherapy Imfinzi (durvalumab).
-
Combined immunotherapies – potential and pitfalls
Likewise, some patients who initially benefit from immunotherapies go on to become resistant. ... This is a major headache for companies testing combination immunotherapies, said Charles Swanton.
More from intelligence
Approximately 4 fully matching, plus 48 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.
-
BMS appoints new commercial leader, Davies joins Eisai and more
The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy. ... Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as
-
Industry appointments
Zelluna Immunotherapy appoints CSO. Norwegian biotech Zelluna Immunotherapy has named Namir Hassan as its chief scientific officer (CSO). ... antigen. Hassan’s new role, however, will see him manage and plan the next stages of development for the TCR
-
Zelluna Immunotherapy appoints chief technology officer
Arjan Roozen will consolidate the biotech’s manufacturing strategy. Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.
-
Targovax strengthens board of directors
of our novel and complementary portfolio of cancer immunotherapies.”.
More from appointments
Approximately 2 fully matching, plus 43 partially matching documents found.
Latest from PMHub
-
Lucid Group welcomes new magical talent and boosts their medical writing teams with hires in the US and UK
With three years’ healthcare communications experience, and a wealth of knowledge in epilepsy, immunotherapy and oncology Andrew comments, “I have had a very fulfilling first two months at Lucid; the team
-
SWITCHED ONcology Patient Experience Focus Group Full Discussion
The focus group provided deeper insight in to a number of themes including the transformation of cancer understanding, the barriers to cancer diagnosis, the advent of new treatments including immunotherapy, communication
-
Training the next generation of biotech leaders
Technology born out of barcodes, tracking and scanning will become critical as we embrace things like cellular immunotherapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to
-
The Big Communication - matching unprecedented clinical advances in immunotherapy with transformative communication
In this white paper, we explore the exciting new frontier of cancer treatment - immuno-oncology (IO) - and what it means for how we communicate with healthcare professionals, patients and carers. For those on the frontline of treating cancer, IO
-
SWITCHED ONcology
We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched ON. Switched ONcology is the latest thought
More from PMHub
Approximately 11 fully matching, plus 13 partially matching documents found.
Featured jobs
-
Health Consultant - Brand Comms
-
Competitive Salary
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Scientific Director – Medical Communications
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Account Director, Medical Education
-
Salary TBC
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Account Manager, Medical Communications, London
-
Excellent package
Subscribe to our email news alerts
- Fishawack acquires Dudnyk
- GSK’s myeloma drug hits target, prompting rapid filing pledge
- Winners of the HSJ Partnership Awards 2019 unveiled
- 50 questions for delivering an exceptional healthcare brand experience
- Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity
- The brand strategy revolution
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- 50 questions for delivering an exceptional healthcare brand experience
- Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
- The brand strategy revolution
- Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
